FLASH Radiotherapy — What It Is, and Whether You Can Actually Get It

The difference is speed, not the radiation itself. A normal radiotherapy session delivers its dose over a few minutes. FLASH radiotherapy delivers a comparable dose in a fraction of a second. In laboratory and animal studies, radiation given that fast appeared to injure healthy tissue less, while still acting on the tumour.

The number that defines it is the dose rate. Conventional external beam radiotherapy runs at roughly 0.03 to 0.1 gray per second, so a 2 gray session takes a minute or two of beam-on time. FLASH is conventionally defined as 40 gray per second or more — several hundred times faster. Everything else about the plan, the imaging and the positioning would still have to happen exactly as it does today.

The observation that made researchers pay attention is called the FLASH effect. In pre-clinical work, normal tissue exposed to an ultra-high dose rate showed less damage than the same dose delivered slowly, without an obvious loss of effect on the tumour. Why that happens has not been settled. The most discussed explanation is that the beam momentarily strips oxygen from the tissue it passes through, changing the chemistry of the damage, but that is a hypothesis under investigation rather than an established mechanism.

It is worth being clear about what this page is not saying. Nobody has shown that FLASH radiotherapy produces better outcomes for patients. It is a promising line of research at an early stage, and it is being reported honestly here because a technology comparison is only useful if the availability column is honest too.

Your radiotherapy is delivered at an NABH-accredited partner centre; CION Cancer Clinics coordinates your treatment plan, your oncology team and your care throughout. CION does not own or operate a linear accelerator, a CyberKnife, a Gamma Knife, or any proton or FLASH facility.

No. As of August 2026, FLASH radiotherapy is not an approved, routine treatment anywhere in the world. It is investigational. Every patient treated so far has been treated inside a registered clinical trial or an investigational protocol at a research centre, with ethics-committee oversight and written informed consent — not as ordinary care.

• No guideline body lists it as a standard option. NCCN, ASTRO and ESMO guidance does not name FLASH as a recommended treatment for any cancer. Modern photon radiotherapy remains the standard approach for the large majority of cancers that need radiation.
• No device is cleared for routine clinical use. Regulators in some countries have permitted investigational use of FLASH-capable equipment inside approved studies. That is a permission to research, not an approval to treat.
• The published human experience is small. It consists of feasibility and safety studies in limited numbers of patients, mainly superficial skin lesions and painful bone secondaries, with short follow-up.
• The endpoint being tested is not the one you care about yet. Early trials ask whether the technique can be delivered accurately and safely. Whether it reduces side effects, or changes outcomes, needs larger studies and years of follow-up.

Late effects of radiation appear months and years afterwards. That is the honest reason a technique cannot be judged on side effects until treated patients have been followed for that long.

No. As of August 2026 there is no FLASH radiotherapy service open to patients in India, as routine care or through a trial we are aware of. Any radiation-producing device used clinically here must be licensed by the Atomic Energy Regulatory Board, and any clinical study must be registered with the Clinical Trials Registry – India and approved by an institutional ethics committee.

This matters practically, because “newest technology” is a phrase that gets used loosely in marketing. Ultra-high dose rate delivery is not the same thing as a fast, modern treatment session, and a centre describing a short session or a high-output linear accelerator is not describing FLASH.

If a centre in India offers you FLASH radiotherapy, ask for three things in writing before you pay a rupee:

• The facility and the device. Which centre, which machine, and who manufactured it. A named device can be checked.
• The regulatory licence. The Atomic Energy Regulatory Board licence covering that device for the use being offered.
• The trial registration. The Clinical Trials Registry – India number and the ethics-committee approval. Investigational treatment is delivered inside a study, and a study has a number.

If those cannot be produced, treat the offer as unverified and take the paperwork to your own oncologist before agreeing to anything. Costs quoted for any radiotherapy are indicative only, as of August 2026, and should always come to you as a written, itemised estimate.

No, and this is the one place on this page where the answer is not balanced. Delaying treatment that is available now, to wait for a technique that is investigational, has no approval and no service in India, is a real clinical risk. There is no published timeline for when either of those things changes.

The instinct behind the question is a good one. Wanting the most current technology usually means wanting fewer long-term side effects, and that is a legitimate thing to press your team on. The useful version of that conversation is about your own plan, not about a machine you cannot access.

Ask your radiation oncologist to show you the planned dose to each organ at risk in your plan, and whether any of them sits near its limit. If every one of them is comfortably within limits, then the sparing that FLASH is being studied for would have little left to improve in your case. If one is close to its limit, that is a specific, answerable problem — and the tools that address it today, including modified fractionation, breath-hold techniques and daily image guidance, are available now.

If you are coordinating for a relative from another city or from overseas, the same rule applies: the question that changes the plan is what the dose numbers look like, not which technology is in the news.

• Is this a registered clinical trial, and what is its registration number? — investigational treatment is delivered inside a study, and a study has a number you can look up.
• Which device is being used, and does it hold a licence for this use? — a named, licensed device can be verified; an unnamed one cannot.
• Am I being asked to pay for investigational treatment? — ask exactly what the payment covers and get it in writing before agreeing.
• What would my standard plan look like instead, and what dose would each organ at risk receive? — ask to see the actual numbers.
• Would waiting for this delay the treatment I could start now, and by how long? — delay is a clinical cost, not only an inconvenience.
• Can my own oncologist review this offer before I commit? — a genuine study will have no problem with a second opinion.

• For shallow skin lesions, low-energy beams that stop just below the surface have been in routine use for decades — Superficial and Orthovoltage X-Ray Therapy for Skin Lesions explains where they fit.
• If your tumour is very large, there is an established approach that deliberately treats it in a pattern rather than uniformly: GRID and Lattice Radiotherapy for Very Large Tumours.
• Electron beams are the same particle most FLASH research uses, and they already have a standard clinical role — see Total Skin Electron Beam Therapy for Skin Lymphoma.
• At the other end of the scale, radiation can be given to the whole body as part of a transplant plan: Total Body Irradiation Before a Bone Marrow Transplant.
• For the full picture of how radiation is planned, delivered and coordinated with NABH-accredited partner centres, see Radiation Therapy at CION Cancer Clinics.

Still not sure what applies to your own tumour? Book a free consultation and a radiation oncologist will go through your scan and your options with you directly.